Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant newcastle disease virus capsids displaying the EV71 VP1 fragment

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1783-1791

  Ch'ng, Wei Choong ^a   Stanbridge, Eric J ^b   Ong, Kien Chai ^c   Wong, Kum Thong ^c   Yusoff, Khatijah ^a   Shafee, Norazizah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Enterovirus 71 infection; Protection; Vaccine

Indexed keywords

NEWCASTLE DISEASE VACCINE; PROTEIN VP1; RECOMBINANT PROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; HINDLIMB; HISTOPATHOLOGY; IMMUNIZATION; INFECTION PREVENTION; LEG MUSCLE; MOUSE; NEWBORN; NONHUMAN; PARALYSIS; SPINAL CORD; SURVIVAL RATE; VACCINATION; VIRAL CLEARANCE; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; CYTOKINES; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; IMMUNIZATION; MICE; NEUTRALIZATION TESTS; NEWCASTLE DISEASE VIRUS; VACCINES, SYNTHETIC; VERO CELLS; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; HUMAN ENTEROVIRUS 71; MIRIDAE; MUS; NEWCASTLE DISEASE VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 80051587691     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22198     Document Type: Article

References (41)

1. Abzug MJ. 2009. Enterovirus 71: Emergence of the new poliomyelitis. South Afr J Epidemiol Infect 24: 5-8.
2. Adkins B, Bu Y, Guevara P. 2001. The generation of Th memory in neonates versus adults: Prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates. J Immunol 166: 918-925.
3. Baxter D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 57: 552-556.
4. Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. 1999. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 354: 987-991.
5. Ch'ng WC, Saw WT, Yusoff K, Shafee N. 2011. Immunogenicity of Newcastle disease virus capsids displaying the EV71 VP1 fragment in mice. Acta Virol, in press.
6. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ. 2000. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: Clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31: 678-683.
7. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9: 78-85.
8. Chang LY. 2008. Enterovirus 71 in Taiwan. Pediatr Neonatol 49: 103-112.
9. Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, Hsu KH, Fang TY, Huang YC, Lin TY. 2004. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 291: 222-227.
10. Chang LY, Shih SR, Huang LM, Lin TY. 2007. Enterovirus 71 encephalitis. In: Fong IW, Alibeck K, editors. New and evolving infections of the 21st Century. New York: Springer, pp 295-325.
11. Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. 2004. A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol 85: 69-77.
12. Chen HF, Chang MH, Chiang BL, Jeng ST. 2006. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: 2944-2951.
13. Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM. 2008. Expression of VP1 protein in the milk of transgenic mice: A potential oral vaccine protects against enterovirus 71 infection. Vaccine 26: 2882-2889.
14. Chiu CH, Chu C, He CC, Lin TY. 2006. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671-1678.
15. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, Gacheva M, Mitov G, Ninov N, Tsylka E, Robinson I, Frolova M, Bashkirtsev V, Martiyanova L, Rodin V. 1979. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60: 329-340.
16. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
17. Ding NZ, Wang XM, Sun SW, Song Q, Li SN, He CQ. 2009. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res 145: 157-161.
18. Foo DG, Alonso S, Chow VT, Poh CL. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299-1306.
19. Hashimoto I, Hagiwara A. 1982. Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: A model for human infection. Neuropathol Appl Neurobiol 8: 149-156.
20. Herrero LJ, Lee CS, Hurrelbrink RJ, Chua BH, Chua KB, McMinn PC. 2003. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997-2000. Arch Virol 148: 1369-1385.
21. Kho CL, Tan WS, Yusoff K. 2001. Production of the nucleocapsid protein of Newcastle disease virus in Escherichia coli and its assembly into ring- and nucleocapsid-like particles. J Microbiol 39: 293-299.
22. Lefrancois L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo. J Virol 51: 208-214.
23. Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S. 2009. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126-1128.
24. McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91-107.
25. Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, Wong KT. 2008. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 67: 532-542.
26. Ong KC, Devi S, Cardosa MJ, Wong KT. 2010. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661-665.
27. Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, Chieng CH, Perera D, Clear D, Wong D, Blake E, Cardosa J, Solomon T. 2007. Human enterovirus 71 disease in Sarawak, Malaysia: A prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis 44: 646-656.
28. Rabu A, Tan WS, Kho CL, Omar AR, Yusoff K. 2002. Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins. Acta Virol 46: 211-217.
29. Roberts GB, Boyd JF. 1987. The histopathology of enterovirus infections of new-born mice. J Infect 15: 45-56.
30. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vriend G. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317: 145-153.
31. Shinohara M, Uchida K, Shimada S, Segawa Y, Hoshino Y. 2001. Characterization of enterovirus type 71 isolated in Saitama Prefecture in 2000. Kansenshogaku Zasshi 75: 490-494.
32. Siegrist CA. 2001. Neonatal and early life vaccinology. Vaccine 19: 3331-3346.
33. Siegrist CA. 2007. The challenges of vaccine responses in early life: Selected examples. J Comp Pathol 137: S4-S9.
34. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K. 2006. Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol 78: 1096-1104.
35. Tan CS, Cardosa MJ. 2007. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 152: 1069-1073.
36. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 281: 1520-1527.
37. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, Su IJ, Wang JR, Yeh TM, Chen SH, Yu CK. 2004. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916-7924.
38. Wong KT, Munisamy B, Ong KC, Kojima H, Noriyo N, Chua KB, Ong BB, Nagashima K. 2008. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol 67: 162-169.
39. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
40. Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, Wang SM, Lei HY, Su IJ, Yu CK. 2007. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 81: 10310-10315.
41. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523-528.